

MED LIFE S.A.

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J40/3709/1996
Subscribed and paid-in share capital: 132,870,492 RON



No. 52 / 31 July 2024

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 24/2017 on issuers of financial instruments and market operations, and the provisions of Article 99 of the Bucharest Stock Exchange Code, Title II, Issuers and Financial Instruments

Report Date: **31 July 2024**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**

Registered Office: **Bucharest, Calea Grivitei, no. 365, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J40/3709/1996**

Subscribed and paid-in share capital: **132,870,492 RON**

Total number of shares: **531,481,968 (out of which 417,042 shares without voting rights and 531,064,926 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Significant events to report:

***Auditor report according with art. 108 of Law no. 24/2017 republished,
for the First Semester of 2024***

MED LIFE S.A. informs investors about the publishing of the Independent Limited Assurance Report for the First Semester of 2024, prepared by the financial auditor Ernst & Young Assurance Services SRL, regarding the information included in the current reports issued by the Company in accordance with the provisions of Article 108 of Law 24/2017, with all subsequent changes and clarifications, and with the provisions of FSA Regulation no. 5/2018.

The auditor report is enclosed to this report.

Mihail Marcu
Chief Executive Officer

Independent Limited Assurance Report on the information included in the current reports issued by the Company in accordance with requirements of Law 24/2017, with all subsequent changes and clarifications, and with the provisions FSA Regulation no. 5/2018

To the Board of Directors of the Med Life S.A.

Purpose of the report

We were engaged by the Med Life S.A. (hereinafter "the Company " to report based on the requirements of Law 24/2017 for issuers of financial instruments and market operations, with all subsequent changes and clarifications (hereinafter referred to as "Law 24/2017") on the information included in the attached current reports dated 25 January 2024 and 27 June 2024 (hereinafter "Reporting Schedules") that have been prepared by the Company in accordance with the requirements of Law 24/2017 and with the provisions of Regulation no. 5/2018 of Financial Supervisory Authority ("FSA") reported to Financial Supervisory Authority ("FSA") and to Bucharest Stock Exchange ("BVB") in the period 1 January 2024 - 30 June 2024, in the form of a limited assurance conclusion.

Specific Purpose

Our report is intended solely for the purpose specified in the first paragraph above and for the Company, BVB and FSA information and will not be used for any other purpose. Our report must not be considered appropriate for use by any other party willing to rely on our work, other than the Company for any purpose and in any context.

Any party other than the Company who obtains access to our report or a copy of it and chooses to rely on it (or part of it) will do so taking their own responsibility. We performed our engagement to be able to report those matters that we must report in a limited assurance report, and not for any other purposes. The current report refers only to the Reporting Schedules and should not be associated with the Company's financial statements or other reports of the Company, individually or taken as a whole.

Responsibilities of the Management of the Company

The Company's management is responsible for the preparation of the Reporting Schedule and performing the transactions reported in accordance with the requirements of the Law 24/2017 and of FSA Regulation no. 5/2018, with subsequent changes and clarifications. In particular, the Company's management is responsible for internal controls being designed, implemented and maintained to prevent the preparation of the Reporting Schedules from being materially misstated, due to fraud or error.

In addition, the Company's management is responsible for ensuring that the supporting documents underlying the preparation of the current Reporting Schedules, as well as the evidence provided to the auditor is complete, accurate and justified.

Auditor's Responsibilities

We conducted our limited assurance engagement in accordance with International Assurance Standards, particularly ISAE 3000 (revised) "*International Standard on Assurance Engagements Other than Audits or Reviews of Historical Financial Information*". These standards require that we comply with ethical standards and plan and perform our assurance engagement to obtain limited assurance about the Reporting Schedules.

We apply International Standard on Quality Management 1, Quality Management for Firms that Perform Audits or Reviews of Financial Statements, or Other Assurance or Related Services engagements, which requires that we design, implement and operate a system of quality management, including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

We comply with the independence and other ethical requirements of the International Code of Ethics for Professional Accountants (including International Independence Standards) as issued by the International Ethics Standards Board for Accountants ("IESBA Code"), which establishes the fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

The procedures selected depend on the auditor's judgment and our understanding of the transactions included in the Reporting Schedules and of other circumstances of the engagement, as well as our consideration of areas where material misstatements may occur. In obtaining an understanding of the reported transactions included in the Reporting Schedules, we considered the process applied by the Company to conclude the transactions and to prepare and present the Reporting Schedules in accordance with the requirements of Law 24/2017 and FSA Regulation no. 5/2018 in order to design audit procedures that are appropriate in these circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control related to concluding the reported transactions or preparation and presentation of the attached Reporting Schedules.

The procedures include, in particular, inquiry of the personnel responsible for financial reporting and risk management and additional procedures aimed at obtaining evidence about the information included in the Reporting Schedules.

The nature, timing and extent of procedures performed in a limited assurance engagement is limited compared with that necessary in a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is considerably lower as compared to the one obtained in a reasonable assurance engagement.

In respect of the Reporting Schedules of the Company, in order to assess correctness and justification of the transactions reported, we have performed the following procedures:

- 1) We have obtained the attached Reporting Schedules from the Company for the current period and the detail of the transactions included in these Reporting Schedules.
- 2) We observed if the approving persons of the Reporting Schedules are the authorised representatives of the Company and we have requested the authorized signatures schedule.

- 3) For the transactions included in the Reporting Schedules, we have considered if the details included of the Reporting Schedules are consistent, in all material respects, with information as per signed contracts/contractual documentation presented to us and that the presented documents have been signed by representatives of the Company that are indicated in the authorized signature schedule provided to us. As applicable, in performing our procedures we have compared information included in the Reporting Schedules to the contract/ contractual documentation for consistency of details on: the parties which signed the supporting documentation; the date when documentation was signed and its nature; the description of the type of goods/services as indicated in the documentation; the actual or estimated total value of the contract/ contractual documentation, and, as applicable, the guarantees constituted and the stipulated penalties, the terms and the method of payment; as well as the related contractual conditions.
- 4) For the transactions included in the Reporting Schedules, we have compared details disclosed in the attached Reporting Schedules for consistency with the information obtained by us based on the inquiries made to the management and other responsible personnel within the Company and based on other documents attached to the contracts, as applicable.
- 5) For the transactions included in the Reporting Schedules, to the extent that there is a market price available for the goods delivered or services rendered between the Company and its related parties, we have discussed with the Company's management the basis for the price determination and considered if, to the extent applicable, the prices agreed are consistent with those applied in the contracts signed with third (other) parties, where similar goods or services could be provided, and if the related contracts are approved by the Board of Directors or Supervisory Board.

To the extent that no market prices are available, we have analyzed if the respective transactions have been performed based on the Company's internal procedures for price determination and if the related contracts are approved by the Board of Directors or Supervisory Board of the Company in accordance with its internal procedures.

Our procedures have been performed, as described above, only on the transactions included in the attached Reporting Schedules, that are published in the period 1 January 2024 - 30 June 2024. We have not performed any procedures to verify whether the Reporting Schedules include all the transactions that the Company has to report according to Law 24/2017 for the current period.


Conclusion

We formed our conclusion on the basis and considering the matters presented in the current limited assurance report. Based on the procedures performed as described above and evidence obtained, nothing has come to our attention that causes us to believe that:

- a) The information included in the Reporting Schedules attached is not, in all material respects, in accordance with the documents provided to us by the Company.
- b) The details included in the attached Reporting Schedules are not, in all material respects, consistent with the requirements of Law 24/2017 and FSA Regulation no. 5/2018 regarding the parties which signed the supporting documentation; the date when documentation was signed and its nature; the description of the type of goods/services as indicated in the documentation; the actual or estimated total value of the contract/agreement documentation, and, as applicable, the guarantees constituted and the stipulated penalties, the terms and the method of payment; as well as the related contractual conditions.

- c) The contracts related to the reported transactions were not properly authorized by representatives of the Company and were not approved by the Board of Directors or Supervisory Board in line with the Company's internal procedures.
- d) The prices have not been established by mutual agreement between the parties in accordance with the type of goods/services and also by considering other terms and conditions mentioned, as applicable, in the agreements between the parties and, respectively, were not determined in accordance with the criteria mentioned at point 5) from the list of procedures detailed above.

On behalf of,
Ernst & Young Assurance Services SRL



Alice Ivanovici
Partner
30 July 2024
Bucharest, Romania

Autoritatea pentru Supravegherea Publică a
Activității de Audit Statutar (ASPAAS)
Firma de audit: ERNST & YOUNG ASSURANCE SERVICES S.R.L.
Registrul Public Electronic: FA77

Autoritatea pentru Supravegherea Publică a
Activității de Audit Statutar (ASPAAS)
Auditor financiar: Ivanovici Alice Andreea
Registrul Public Electronic: AF3617

Attachment

1. Reporting Schedules

MED LIFE S.A.

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J40/3709/1996
Subscribed and paid-in share capital: 132,870,492 RON



No. 4 / 25 January 2024

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations and Law no. 24/2017 on issuers of financial instruments and market operations

Report Date: **25 January 2024**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "The Company")**

Registered Office: **Bucharest, Calea Grivitei, no. 365, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J40/3709/1996**

Subscribed and paid-in share capital: **132,870,492 RON**

Total number of shares: **531,481,968 (out of which 162,984 shares without voting rights and 531,318,984 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Significant events to report:


Report on transactions with related parties according to art. 108 of Law no. 24/2017, republished

During the period April – October 2023, according to the last closed trial balance, Med Life S.A. has concluded / executed transactions with related parties that exceed cumulatively, 5% of the company's net assets according to the latest published standalone financial report of Med Life S.A. (for the Third Quarter of 2023) i.e., RON 14,872,474, as follows:

- transactions between Med Life S.A. and Bahtco Invest S.A. in total amount of RON 18,388,319.

The transactions concluded / executed between April – October 2023, as well as the outstanding mutual debt are presented in Annex 1, enclosed to this report.

Mihail Marcu
Chief Executive Officer



A handwritten signature in blue ink, appearing to be a stylized representation of the name Mihail Marcu.

Annex 1

No.	Contracting parties		Contract Identification		Information on addendums		Main contractual information										Mutual liabilities as at 31st of October 2023 (RON)	
	Beneficiary	Provider	Contract No.	Contract Date	Addendum No.	Addendum Date	Object	Guarantees provided	Payment Term	Payment method	Penalties	Month and year	Transactions	15	16			
1	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Apr-23	703,113					
2	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Apr-23	426,028					
3	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	Maintenance charges - re-invoicing	-	-	-	-	Apr-23	22,006					
4	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	-	Apr-23	37,722					
5	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	Payment order	-	Apr-23	25,306					
6	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	Payment order	-	Apr-23	21,885					
7	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	Payment order	-	Apr-23	112,330					
8	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Reimbursement for loan (RON)	-	-	Payment order	-	Apr-23	(500,000)					
9	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	May-23	988,081					
10	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from	May-23	428,089					

Ernst & Young Assurance Services SRL
 3.0. IUL. 2024
 Signed for identification
 Semnat pentru identificare

ED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania
 Unique Registration Code at the National Office of Trade Registry: 8422035
 Order number on the Trade Registry: J40/3709/1996
 Subscribed and paid-in share capital: 5.536.270,5 RON



25	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Jul-23	736,767	
26	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	-	Rent	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Jul-23	425,968	
27	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	-	Maintenance charges - re-invoicing	Maintenance charges - re-invoicing	-	-	-	-	Jul-23	22,090	
28	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	-	Utilities - re-invoicing	Utilities - re-invoicing	-	-	-	-	Jul-23	6,393	
29	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	-	Interest for the amount due to MedLife SA	Interest for the amount due to MedLife SA	-	-	Payment order	-	Jul-23	26,146	
30	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	-	Interest for loan (EUR)	Interest for loan (EUR)	-	-	Payment order	-	Jul-23	22,611	
31	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	-	Interest for loan (RON)	Interest for loan (RON)	-	-	Payment order	-	Jul-23	169,216	
32	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	-	Withdrawals for loan (RON)	Withdrawals for loan (RON)	-	-	Payment order	-	Jul-23	5,000	
33	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	-	Reimbursement for loan (RON)	Reimbursement for loan (RON)	-	-	Payment order	-	Jul-23	(797,500)	
34	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	-	Acquisition of materials	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Aug-23	984,422	
35	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	-	Rent	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Aug-23	426,537	
36	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	-	Maintenance charges - re-invoicing	Maintenance charges - re-invoicing	-	-	-	-	Aug-23	21,962	

Ernst & Young Assurance Services SRL
30 JUL 2024
 Signed for identification
 Semnal peatru identificare

ED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania
 Unique Registration Code at the National Office of Trade Registry: 8422035
 Order number on the Trade Registry: J40/3709/1996
 Subscribed and paid-in share capital: 5.536.270.5 RON



37	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	-	Aug-23	78,331	
38	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	-	Payment order	Aug-23	26,187	
39	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	-	Payment order	Aug-23	22,647	
40	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	-	Payment order	Aug-23	113,858	
41	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Withdrawals for loan (RON)	-	-	-	Payment order	Aug-23	1,300,000	
42	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	-	Payment order	Sep-23	962,911	
43	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	-	Payment order	Sep-23	429,420	
44	Med Life SA	Bahtco Invest SA	-	03.01.2021	-	-	Maintenance charges - re-invoicing	-	-	-	-	Sep-23	21,991	
45	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	-	Sep-23	4,568	
46	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	-	Payment order	Sep-23	25,508	
47	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	-	Payment order	Sep-23	22,059	
48	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	-	Payment order	Sep-23	110,379	
49	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	-	Payment order	Oct-23	951,869	Liabilities
50	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	-	Payment order	Oct-23	428,756	1,393,582

Ernst & Young Assurance Services S.R.L.
3-0. IUL. 2024
 Signed for identification
 Semnat pentru identificare

MED LIFE S.A.

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J40/3709/1996
Subscribed and paid in share capital: 132,870,492 RON

No. 44 / 27 June 2024

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations and Law no. 24/2017 on issuers of financial instruments and market operations

Report Date: **27 June 2024**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "The Company")**

Registered Office: **Bucharest, Calea Grivitei, no. 365, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J40/3709/1996**

Subscribed and paid-in share capital: **132,870,492 RON**

Total number of shares: **531,481,968 (out of which 417,042 shares without voting rights and 531,064,926 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Significant events to report:


Report on transactions with related parties according to art. 108 of Law no. 24/2017, republished

During the period November 2023 – May 2024, according to the last closed trial balance, Med Life S.A. has concluded / executed transactions with related parties that exceed cumulatively, 5% of the company's net assets according to the latest published standalone financial report of Med Life S.A. (for the First Quarter of 2024) i.e., RON 16,391,719, as follows:

- transactions between Med Life S.A. and Bahtco Invest S.A. in total amount of RON 18,122,359.

The transactions concluded / executed between November 2023 – May 2024, as well as the outstanding mutual debt, are presented in Annex 1 enclosed to this report.

Mihail Marcu
Chief Executive Officer



MED LIFE S.A.

Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania
 Unique Registration Code at the National Office of Trade Registry: 8422035
 Order number on the Trade Registry: J40/3709/1996
 Subscribed and paid-in share capital: 132,870,492 RON



Annex 1

No.	Contracting parties		Contract Identification		Information on addendums		Main contractual information						Mutual liabilities as at May 31st 2024 (RON)		
	Beneficiary	Provider	Contract No.	Contract Date	Addendum No.	Addendum Date	Object	Guarantees provided	Payment Term	Payment method	Penalties	Month and year	Transactions	15	16
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
1	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Nov-23	1,027,750		
2	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Nov-23	429,248		
3	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	Maintenance charges - re-invoicing	-	-	-	-	Nov-23	33,057		
4	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	-	Nov-23	(4,100)		
5	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	Payment order	-	Nov-23	25,498		
6	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	Payment order	-	Nov-23	22,050		
7	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	Payment order	-	Nov-23	108,148		
8	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Withdrawals for loan (RON)	-	-	Payment order	-	Nov-23	210,000		
9	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Dec-23	759,209		
10	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	Payment order	Daily penalties in amount of 0.01% from outstanding balance	Dec-23	429,420		
11	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	Maintenance charges - re-invoicing	-	-	-	-	Dec-23	37,101		

Ernst & Young Assurance Services S.R.L.
3-0. IUL. 2024
 Signed for identification
 Semnat pentru identificare

ED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania
 Unique Registration Code at the National Office of Trade Registry: 8422035
 Order number on the Trade Registry: J40/3709/1996
 Subscribed and paid-in share capital: 5,536,270.5 RON



12	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	-	Dec-23	2,707
13	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	-	Payment order	Dec-23	370,284
14	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	-	Payment order	Dec-23	320,222
15	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	-	Payment order	Dec-23	814,139
16	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Reimbursement for loan (RON)	-	-	-	Payment order	Dec-23	(1,575,000)
17	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Withdrawals for loan (RON)	-	-	-	Payment order	Dec-23	1,050,000
18	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	-	Payment order	Jan-24	904,172
19	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	-	Payment order	Jan-24	429,619
20	Med Life SA	Bahtco Invest SA	Re-invoicing agreement no 1	03.01.2021	-	-	Maintenance charges - re-invoicing	-	-	-	Payment order	Jan-24	18,110
21	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Utilities - re-invoicing	-	-	-	Payment order	Jan-24	3,345
22	Bahtco Invest SA	Med Life SA	2	07.10.2011	2	01.12.2022	Interest for the amount due to MedLife SA	-	-	-	Payment order	Jan-24	55,715
23	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (EUR)	-	-	-	Payment order	Jan-24	48,182
24	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Interest for loan (RON)	-	-	-	Payment order	Jan-24	176,263
25	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Withdrawals for loan (RON)	-	-	-	Payment order	Jan-24	1,765,000
26	Med Life SA	Bahtco Invest SA	-	01.06.2011	-	-	Acquisition of materials	-	90 days from the date when the invoice was issued	-	Payment order	Feb-24	986,877
27	Med Life SA	Bahtco Invest SA	-	27.05.2011	2	01.04.2022	Rent	-	30 days from the date when the invoice was issued	-	Payment order	Feb-24	428,937

Ernst & Young Assurance Services SRL
 3.0. IUL. 2024
 Signed for identification
 Semnat pentru identificare

ED LIFE S.A.

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J40/3709/1996
Subscribed and paid-in share capital: 5.536.270,5 RON



56	Bahtco Invest SA	Med Life SA	1	15.12.2010	2	01.12.2022	Withdrawals for loan (RON)	-	Payment order	-	May-24	395,000	
----	------------------	-------------	---	------------	---	------------	----------------------------	---	---------------	---	--------	---------	--

Total transactions 18,122,359

EY
Ernst & Young Assurance Services S.R.L.
3-0 JUL 2024
Signed for identification
Semnal pentru identificare